DJ Baker, JA Timmons, PL Greenhaff - Diabetes, 2005 - Am Diabetes Assoc Inhibition of hepatic glycogen phosphorylase is a promising treatment strategy
for attenuating hyperglycemia in type 2 diabetes. Crystallographic studies
indicate, however, that selectivity between glycogen phosphorylase in ... Cited by 16 - Related articles - BL Direct - All 5 versions
DJ Baker, JA Timmons, PL Greenhaff - 糖尿病学杂志, 2005 - journal.shouxi.net Inhibition of hepatic glycogen phosphorylase is a promising treatment strategy
for attenuating hyperglycemia in type 2 diabetes. Crystallographic studies
indicate, however, that selectivity between glycogen phosphorylase in ... Related articles - Cached
DJ Baker, PL Greenhaff, A MacInnes, JA … - Diabetes, 2006 - Am Diabetes Assoc Glycogen phosphorylase inhibition represents a promising strategy to suppress
inappropriate hepatic glucose output, while muscle glycogen is a major source of
fuel during contraction. Glycogen phosphorylase inhibitors (GPi) currently ... Cited by 10 - Related articles - BL Direct - All 7 versions
- ►nih.gov [PDF] C Lerín, E Montell, T Nolasco, M García- … - Biochemical Journal, 2004 - pubmedcentral.nih.gov Pharmacological inhibition of liver GP (glycogen phosphorylase), which is
currently being studied as a treatment for Type II (non- insulin-dependent)
diabetes, may affect muscle glycogen meta- bolism. In the present study, we ... Cited by 9 - Related articles - BL Direct - All 7 versions
SW Wright, VL Rath, PE Genereux, DL … - Bioorganic & medicinal chemistry letters, 2005 - Elsevier We sought to identify novel allosteric chloroindole inhibitors of GPa that were
structurally distinct from the norstatine series of inhibitors previously
reported by us. 9 In particular, we wanted to explore an achiral ... Cited by 10 - Related articles - All 5 versions
AK Ogawa, CA Willoughby, R Bergeron, KP … - Bioorganic & Medicinal Chemistry Letters, 2003 - Elsevier A recent World Health Organization report estimates that approximately 130
million people worldwide are afflicted with type 2 diabetes.[1] Patients suffer
from reduced insulin sensitivity and secretion that result in glucose ... Cited by 20 - Related articles - All 4 versions
… MN Kosmopoulou, ED Chrysina, DD Leonidas … - Protein Science: A Publication of the Protein Society, 2005 - pubmedcentral.nih.gov Acyl ureas were discovered as a novel class of inhibitors for glycogen
phosphorylase, a molecular target to control hyperglycemia in type 2 diabetics.
This series is exemplified by 6-{2,6-Dichloro- 4-[3-(2-chloro-benzoyl)- ... Cited by 8 - Related articles - BL Direct - All 9 versions
NG Oikonomakos, M Kosmopoulou, SE Zographos … - European Journal of Biochemistry - interscience.wiley.com Two substituted ureas of β-d-glucose, N-acetyl-N'-β-d-glucopyranosyl urea
(Acurea) and N-benzoyl-N'-β-d-glucopyranosyl urea (Bzurea), have been
identified as inhibitors of glycogen phosphorylase, a potential target for ... Cited by 27 - Related articles - BL Direct - All 7 versions
[CITATION] Rabbit muscle glycogen phosphorylase b. The structural basis of activation and catalysis …
NG Oikonomakos, KR Acharya, LN Johnson - CRC Press: Roca Raton81–151. In: Harding JJ, Crabbe … Cited by 2 - Related articles
